Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

FDA Grants Orphan Drug Designation to LMP744 for Glioma

October 11th 2024

LMP744 has been granted orphan drug designation by the FDA for the treatment of patients with glioma.

EU Green Lights CLDN18 RxDx Assay As Companion Diagnostic for Zolbetuximab in Gastric Cancer

October 11th 2024

CE certification was granted to the VENTANA CDLN18 RxDx assay for the assessment of CLDN18 protein expression in gastric or GEJ adenocarcinoma in Europe.

NMPA Grants Marketing Approval to NGS-Based Companion Diagnostic for Sunvozertinib in EGFR Exon 20+ NSCLC

October 11th 2024

A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.

VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies

October 11th 2024

Complete responses were achieved by 2 patients with advanced CD123-positive hematologic malignancies who received VIP943 in a phase 1 study.

Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses how breast cancer awareness efforts can enable earlier detection, better disease management, and improved patient outcomes.

Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced Toxicity in CML

October 10th 2024

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation

October 9th 2024

Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.

JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management

October 8th 2024

Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.

D-VRd Propels Toward SOC Status in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

October 8th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, expands on data from the CEPHEUS trial of D-VRd in transplant-ineligible/-deferred, newly diagnosed multiple myeloma.

Dr Ahn on Outcomes With Ovarian Function Suppression in HER2+ Breast Cancer

October 8th 2024

Sung Gwe Ahn, MD, PhD, discusses an exploratory analysis of ovarian function suppression in patients with HR-positive, HER2-positive breast cancer.

Dr Truong on Targeted Therapy vs Immunotherapy in BRAF V600–Positive Melanoma

October 7th 2024

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial investigating the switch from targeted therapy to immunotherapy in advanced BRAF V600+ melanoma.

Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC

October 7th 2024

Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.

Health Canada Expands Indication for Illuccix Diagnostic Kit for PSMA-Targeted Radioligand Therapy in mCRPC

October 7th 2024

Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.

ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML

October 7th 2024

ELVN-001 generated prolonged signals of clinical activity with a tolerable safety profile in patients with TKI-relapsed, -refractory, or -intolerant CML.

Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC

October 4th 2024

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC

October 4th 2024

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

Real-World Analysis Shows High, Durable Transfusion Independence Rates With Luspatercept in Lower-Risk MDS

October 3rd 2024

Luspatercept generated high rates of durable transfusion independence for patients with lower-risk myelodysplastic syndrome in a real-world analysis.

Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC

October 3rd 2024

Mark Awad, MD, PhD, discusses the significance of the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC

October 3rd 2024

Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.

BPd Maintains QOL vs PVd, Supporting Its Use as a New SOC in R/R Myeloma

October 2nd 2024

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.